Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Gubra A/S is a biotechnology company focused on the research and development of peptide-based therapeutics and innovative technologies for the treatment of obesity, diabetes, and related metabolic disorders. The company's core business includes providing preclinical contract research services with an emphasis on metabolic and fibrotic diseases. Gubra is headquartered in Hørsholm, Denmark. The company emphasizes its expertise in translational models and histology, supporting its unique strategic positioning in the biotech contract research space. By integrating computational biology with experimental data, Gubra aims to deliver comprehensive insights that aid in drug discovery and development.
View stock
VS
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
View stock

Stock highlights

Stock comparison highlights
Stock name
Gubra A/SJohnson & Johnson
Last price
€38.75$263.81
Currency
EUR
USD
€648M$621B
-39.15
-€1.49$6.58
0.320.21
0$5.28
02.08%
Sector
HealthHealth
Employees
330138,200
Ticker
€GUBRA$JNJ
Primary listing
XGATNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in €GUBRA or $JNJ on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.